World Health Organization (WHO)

Since its postwar founding, the UN agency has garnered both praise and criticism for its response to international public health crises, including a new coronavirus pandemic in 2020.
Jun 2, 2022
Since its postwar founding, the UN agency has garnered both praise and criticism for its response to international public health crises, including a new coronavirus pandemic in 2020.
Jun 2, 2022
  • Public Health Threats and Pandemics
    Major Pandemics of the Modern Era
    For more than a century, countries have wrestled with how to improve international cooperation in the face of major outbreaks of infectious diseases. The COVID-19 pandemic, which brought the world to a near halt in 2020 and killed nearly seven million people, underscored the urgency.
  • Health
    Public Health Policy in Transition
    Play
    Thomas J. Bollyky, Bloomberg chair in global health at CFR, discusses recent changes to domestic and international health policies and the implications of a U.S. withdrawal from the World Health Organization (WHO) on global health programs and international health coordination. Manisha Juthani, commissioner of the Connecticut Department of Public Health, discusses how state health systems might be affected by changes in federal policies, trusted resources for public health data, and how state and local officials can respond to promote health and safety in their communities. A question-and-answer session follows their opening remarks. TRANSCRIPT FASKIANOS: Thank you. And welcome to the Council on Foreign Relations State and Local Officials Webinar. I’m Irina Faskianos, vice president of the National Program and Outreach here at CFR. CFR is an independent, nonpartisan membership organization, think tank and publisher focused on U.S. foreign policy. CFR is also the publisher of Foreign Affairs magazine. As always, CFR takes no institutional positions on matters of policy. Through our State and Local Officials Initiative, CFR serves as a resource on international issues affecting the priorities and agendas of state and local governments by providing background and analysis on a wide range of policy topics. We’re delighted to have you with us for today’s discussion. We have more than 580 state and local officials confirmed to join us from forty-nine states and two U.S. territories. So, again, this webinar is on the record. The video and transcript will be posted on our website after the fact, at CFR.org. We are pleased to have Tom Bollyky and Manisha Juthani with us to speak on recent changes in public health policy and implications for state and local governments in the United States. We’ve shared their full bios with you, so I will just give you a few highlights. Thomas Bollyky is the inaugural Bloomberg chair in global health at CFR and director of CFR Global Health Program. He is also a senior fellow for international economics, law, and development, and a senior consultant to the Coalition for Epidemic Preparedness Innovations. Tom Bollyky is the founding editor of Think Global Health, an online magazine that examines the ways health shapes economies, societies, and everyday lives around the world. And prior to working at CFR, he served in a variety of positions, including at the office of the U.S. Trade Representative and as a staff attorney at the AIDS Law Project. Manisha Juthani is the commissioner of the Connecticut Department of Public Health. Commissioner Juthani previously served as a professor of medicine and infectious diseases physician at Yale's School of Medicine and currently serves as an adjunct professor there. During the COVID-19 pandemic, Dr. Juthani was a leader in the COVID response at Yale, which led to her appointment as commissioner of the Connecticut Department of Public Health in 2021. So thank you both for being with us today. Tom, I’m going to first turn to you to talk about the most significant changes that we’ve seen to U.S. public health policy in the last month, and what you see is the implication of these changes for future international health coordination and data collection efforts. BOLLYKY: Great. Thank you all for joining us. Thank you to Irina and her team for coordinating this. The state and local network that her team operates is really one of the most useful, I find, resources at CFR, particularly on public health where battles are won at the state and local level. And it’s a privilege to be able to engage with you and learn from what you’re hearing on these issues as well. There's a lot going on, of course, on U.S. public health. So there's a good bit we could talk about. In my initial remarks, I'm really just going to focus on three areas. To start, I'm going to talk about vaccination. And there has been an unfortunate consequence, the cumulative effect of some of the early actions taken over this last month to perhaps undermine the support for vaccination, at a time where we have a quite a large measles outbreak ongoing, the potential emergence of dangerous avian influenza. These are risks not just for a loss of life. On measles, of course, it's also just a huge expense if it shows up in your part of the country. This is new. Vaccination for decades—U.S. immunization efforts provided immense benefits for health and had broad bipartisan support. Underlying these efforts were policies rooted in science that have been adapted and improved over time. Support for that vaccine policy framework is just as important today as it has been ever before. But it really has taken a hit, particularly after the COVID-19 crisis. To see how far we’ve traveled on measles, it was just in 2000 that measles was officially eliminated from the United States—meaning there was no measles spreading in the country. That was driven by vaccination. Typically, you need about—vaccine coverage of around 93 to 95 percent to have a sufficient level of population immunity to prevent outbreaks. There are currently, out of the forty-nine states reporting vaccination rates at the kindergarten level, thirty-one states are below the lower band of that threshold of 93 percent for coverage for the MMR vaccine. In terms of the outbreak, I’m sure most on this call are aware. Yesterday the tragic news was reported of the death of a child from measles in west Texas. An unvaccinated child is the first death from measles in the United States in ten years. Officials have reported, by last count that I’ve seen, 124 cases in Texas, mostly west Texas, since late January. Nine cases in the neighboring New Mexico county. Eighty percent of these cases involve children, who are more susceptible to this vaccine-preventable disease. Vaccination rates in the most affected county, rural Gaines County, at the center of the outbreak, are quite low. We've seen cases in seven other states—Alaska, California, Georgia, New Mexico, of course, New Jersey, New York, and Rhode Island. The total number of cases being just over 130 cases actually is more than we've seen in eight of the last fifteen years. And that's just in the first two months of this calendar year. There are probably more cases than that than we know about. We don't know how large this is going to get, but the rate of increase or the force of infection, as you might say, is strong. For reference, the last major measles outbreak we've had in the United States was in New York in 2019. That hit over a thousand cases. This could be worse. Now it is not too late. With the—with the potential for vaccination, behavioral shifts, tireless work of public health teams we could slow the spread of this outbreak. But it is concerning. At the federal level, we've not seen the type of support one would typically see for vaccination. The CDC has—itself, has been quiet on these issues—relatively quiet. We've had a number of important vaccine advisory committees postponed. The National Vaccine Advisory Committee was meant to discuss the strategic plan for national vaccination in February. That's been postponed. The Advisory Commission on Childhood Vaccination was meant to discuss the vaccine Injury Compensation Program. That's been postponed. There's been questions coming out of—at the secretary level about potential conflicts of interest among the Advisory Committee on Immunization Practice, that considers clinical information on immunization practice. Its findings influence the compensation program. Their credibility has been put in question. We had a Cabinet meeting yesterday at the White House where a reporter afforded an opportunity both to the president and the HHS secretary to speak on this, and although they did, we didn't see the call for vaccination that you would ordinarily see. We also saw in the early days of the administration an executive order restricting any federal funding to states or schools that required COVID-19 vaccination. So a broader—the cumulative effect of these actions, intended or otherwise, diminishes support for vaccination at a point where it's more critical. The second thing I would highlight is the firings of U.S. public health officials as part of the broader reduction of government workers. We’ve seen the National Institutes of Health, the nation’s premier biomedical research agency—we’ve seen an estimated number of a hundred—oh, I’m sorry—1,200 employees, most of them promising young investigators slated for larger roles, have been dismissed. Many of them have specialized knowledge that can’t easily be replaced. The CDC has seen a reduction of around 1,100 individuals. Four hundred of those are people that took the voluntary retirement in response to the request from the Office of Personnel Management. About 750 have been fired. There had been views that we might see a reduction in the Emergency Intelligence Service. Not yet, although that’s still possible. But we have seen significant decreases in personnel in the Laboratory Leadership Service Program, the Public Health Associate Program. And these are linkages between the CDC and states and locality that provide important resources in emerging outbreaks and crises. The last thing I will say is these, of course, also link to what's been happening at the international level, and the information sharing that can go on there. On the first day in office, the president, as many expected, withdrew from the World Health Organization. He did so in a manner that he renewed the withdrawal notice from 2020, suggesting it may be immediate. U.S. officials have already stopped participating in many of the networks that exist around surveillance of emerging infections and around influenza. USAID last night had 580—I’m sorry—5,800 out of 6,200 contracts terminated, in terms of its programming. There’s an expectation that the workforce there will be reduced from around 10,000 to 1,000. And, of course, they provide our eyes and ears with other countries in terms of emerging infections, as well as the good work that USAID does around HIV, malaria, and other concerns. What this boils down to is, you know, frontline public health workers here in the U.S. and abroad provide our network that we detect emerging diseases, prevent and respond to these threats, and protect everyone. That system may be unraveling. The risk of doing so is that we create blind spots, where emerging health threats incubate beyond our knowledge and provide an illusion of safety in public health that we don't—that we don't have. And that is our greatest threat potentially moving forward. So let me stop there. Lots more we can talk about. Looking forward to this exchange. FASKIANOS: Thank you, Tom. And we’re going to go to the commissioner to talk about how you are adapting your health systems in Connecticut to the federal public health policies that are obviously shifting, and the challenges that you’re facing, and where you see the opportunities, so we have a little bit of optimism. (Laughs.) So over to you. JUTHANI: Thank you very much, Irina. Thank you for the opportunity to speak with all of you today. And thank you for laying that foundation, Tom, so that I can speak to how we are dealing with things at the local level and at the state level. So what I would like to start with is that, as we entered these last few months and have seen a number of different orders and actions come through, it has been a time period of uncertainty and a time period of unrest, a bit, in terms of staff in a public health department, and state government writ large. So for us in the Department of Public Health in Connecticut, we have 154 different grants that we receive, largely from the federal government, spanning potentially up to seventeen different agencies at the federal government. And I believe that almost all of them received some sort of cease order in terms of work, initially. Half of my department is funded through federal dollars. And so where we are right now with different temporary restraining orders that have been put in place is that, in fact, at this moment, right now today, we do not have any specific grants that have been given specific terminations or reductions. We also have CDC employees—for example, the EIS officer, CEFOs, which are epidemic field officers that have been positioned in Connecticut—we had threats that they would be fired but they have not, up until this point. So what this has created, though, is a lot of uncertainty in terms of where we are going to be able to move forward, where we are going to potentially have to cut back, and where our work will continue. I think the second point on uncertainty is that, as with all administrations, there's an opportunity to decide what communications should go out, what needs to be paused, what can be resumed. And there was a lot of uncertainty in the first several weeks in terms of what information we would be able to get. And for example, there was the Morbidity and Mortality Weekly Report. The one that was put on pause in the first week after Inauguration Day had three different reports on H5N1 or avian flu. Since then, those have all been published, and we do have that information available. Today another MMWR came out as expected. So that is hopeful, that we have been able to see some resumption of communication that had been paused in the first several weeks. I would also comment that we’ve had a few emergent situations where we’ve had to call the CDC for emergency input in terms of how to deal with potential threats. And we were able to get in touch with officers who were working on the ground and be able to help provide us with guidance. As Tom mentioned, a lot of public health—good, old-fashioned public health is done at the local level, at the state level. But where we do really rely on federal partners is for expertise in areas that maybe we only interact with or have exposure to on a one-off basis and not on a regular, standing basis. And that is one of the challenges that we have seen, that we anticipate, and then we worry about in terms of where that is going to take us going forward. Tom mentioned a little bit about vaccinations. I mean, this is a foundational component of our public health advances over the last century. I’ve been talking for the last several months about a Morbidity and Mortality Weekly Report, MMWR report, from 1999 talking about the ten landmark achievements in public health over that previous century. And many of the things that are in there, with vaccinations being one of the top of the list, are the types of things that we worry about every day. If you look back to the early 1900s, influenza was a leading cause of death in this country. Today, we look at diseases like heart disease, and stroke, and diabetes, and cardiovascular disease taking a higher standpoint than influenza. But that is something that can backtrack very quickly. Something that gave me pause today was when I heard that VRBPAC, which is the federal committee that meets to determine which strains of influenza will be in the next season’s flu vaccine, that meeting was canceled. I hope that it is a postponement. I hope that we have an opportunity to see that those particular candidate selections of what should be in next season's flu vaccine are determined pretty quickly because this takes time. When the flu vaccine is identified what should be in the next season, that has to be done in the spring. It takes time to manufacture these vaccines. And this could be threatening to our pharmaceutical industry. This could have impacts on people showing up for work. The impacts of health are so vast. They impact business every single day. They cannot be separated. Health and business go hand in hand because in order to be thriving members of society we need to be healthy and we be able to—we need to be able to live, and work, and participate with each other. So these are some areas of concern, but I am hopeful that we’ve seen some changes where, for example, MMWR did resume. I am a member through the Association of State and Territorial Health Officials on the ACIP, which is the immunization practice committee that evaluates all—you know, all vaccines that come forward to be able to help create that schedule of vaccines. That meeting was postponed. I am hopeful, again, that ACIP will resume and that we will have an opportunity to be able to resume those types of, really on a regular basis, meetings that help inform these things. In Connecticut, we have been fortunate that vaccine uptake is something that has always been strong in our state. Going back to 2014, since we were talking about measles, the measles, mumps, and rubella vaccine, we had a 96.65 percent uptake for kindergarteners with the MMR vaccine. We hit a low during the pandemic in 2020 of 95.28 percent, with 95 percent often being a quoted number for achieving herd immunity. But now in 2024, we are actually higher than we were pre-pandemic, at 97.7 percent. And so we have a lot to, at least, hope that, at least, we’ll be able to, hopefully, avoid a measles outbreak. But we do have under-vaccinated populations, even within that—within our state. Which is true across the country. And so this is something we worry about, and we prep for, and we try to be ready for. The other thing I want people to just be aware of is that vaccinations are a critical thing, but there are so many areas of public health that we often don’t even think about. And I often say this comment that was said to me once, which is that public health saved your life today, you just didn’t know it. So, for example, safe drinking water. If we take our foot off the gas on regulations for drinking water, whether it be toxins, whether it be chemicals, whether it be infectious agents, these are foundational things that we maintain safety in our country. That is something that is under our purview in the Connecticut Department of Public Health. Another example would be food safety. We’ve heard some concerns that there may be less oversight or regulation in terms of food safety. We know right now, for example, there’s a listeria outbreak that’s going on around the country. This is particularly concerning for women, for babies. And we’ve had two cases here in Connecticut. But this is true at our restaurants and at our distributors of food, right at the ground level. For example, our state health department has secret shoppers that go out and buy different types of meat, or dairy, or produce, and do testing to ensure that food that is out in the public that people can purchase is safe. And we get funded, often through collaborations with the federal government and with our state partners, for that type of safety. These are basic things that public health does. And so I'm hopeful because I've seen some things improve over the last several weeks. But I have areas of concern. And it is our goal to work with our federal partners, that we rely on to be able to help provide us expertise and make these broad decisions that implicate all of us and have potential impacts on all of us. And I really hope that going forward we'll be able to continue to work together with federal partners to ensure the safety in our states. Thank you. FASKIANOS: Thank you very much to you both. Let's go now to all of you for your questions and comments. And you can also use this forum to share your experience and your best practices. (Gives queuing instructions.) And nobody’s put up their hand yet. Oh, we do have the first hand. Jennifer Herring. Q: Good afternoon. I’m Jen Herring. I’m from Doylestown Township, Pennsylvania. I’m the chairman of the Board of Supervisors there. My question is, generally speaking we know that there’s—it looks like there’s some limitations on communication between the federal authorities and state and local authorities, as far as health is concerned. And I’m fearful that it’s going to increase—or, actually, decrease—less communication. Where would you recommend we get our information from, if we don’t have access to the information such as, like, a department—the CDC? JUTHANI: I can start with that, at least. I would say that I would lean into your state public health department. One of the challenges that we all face is that state public health departments and local public health departments often rely on the CDC for more expert guidance. But, you know, we're doing the best we can with the information we have, at least at the local level, for what we can communicate out. And so I think as it relates to what's happening right in front of you, and in probably your day-to-day life at a local level, your state health department is probably a good place and a good resource to be able to lean into. One of the challenges we have, to Tom’s point earlier, is we don’t know what we don’t know. When you don’t have eyes on what’s happening on a more global landscape, or potentially even at the federal level, we just may not know it. But one of the things that I would say is that a number of us, as state health officials, do get together on a weekly basis. We do share information with each other. And we may need to do that a little bit more organically. We have sent out statements as we’ve received them. I’ll give an example. Today's MMWR did comment on severe influenza in children resulting in encephalitis and more severe neurologic complications. Before I heard that in the MMWR, I had heard that from some other state health officials. And so that was something we actually also ended up sending out a notice to providers in Connecticut to let us know if they had children who were manifesting with those types of symptoms. I was glad to see that it showed up in the MMWR as well, and I was able to get a better sense of what is the CDC seeing right now in terms of how that relates to what's happening now as opposed to historically. And some of the information shared there is that right now it seems to be 13 percent of children who died from influenza this season had that presentation, historically that was 9 percent. Again, is that outside of the range of variation? We don’t really know, but that was at least helpful for me to be able to read and understand that that was something they were able to share with us. But I would very much lean into, at least from a day-to-day standpoint of your life, leaning into your local and state health departments. Now, if you’re traveling somewhere else often we might have relied on the CDC to be able to see are there certain health advisories or other things like that that may be out there. I have not seen that that is not there. So that may still be available. But I would say also looking at those specific countries and seeing what they may be reporting out on—and, you know, WHO does have a website, it has information out there. Those would be the types of things I would lean into. FASKIANOS: Tom. BOLLYKY: Great. In the arena of more positive developments, after a few weeks where much of CDC’s website, in terms of data and pages, were shut down, there has been a return of much of that information. Now, depending on the area looking there are some concerns that some demographic information has been stripped out, which, from a public health standpoint, is not always helpful. But a lot of the data that had been missing, and some of the advisories that are posted on the CDC website, have returned. So that is, depending on your area, a resource. So, for instance, when I was looking for how many states are below the threshold, at this point, you can get that information from the CDC website, whereas just a few weeks ago you could not. So you’re starting to see some of those resources come online. The only thing I'll say on the WHO side, there are concerns—leaving aside the issue of collaboration with U.S. officials and, you know, a significant number of U.S. public have health staff had been seconded to the CDC—or, to WHO, so it was a real resource there, this will be—the United States was the largest donor to WHO, representing around 16 percent of its overall budget. So they have stopped international travel by most staff unless you're locally there. So to get back to the point that we don't know what we don't know, there is going to be some diminution of the international information we have, simply by reducing the reach of the world's health agency. So that will come at a cost. And part of that cost is the collaboration and the movement of staff. FASKIANOS: I’m going to take the next question from council member Barbara Leary from Folsom, California. Q: Yeah, I’m wondering if there’s—and I don’t know what can be done about this—any movement to reinstate a lot of the research? I know, you know, that you’ve talked, you know, about the MMWR being re-released, but I guess I’m concerned about a lot of scientists and other people who have been let go or who are not being able to pursue their interests in research, tracking problems, et cetera. And does anybody have any idea about how that might be addressed or changed? I think we’re in uncharted territory at this point, so just looking for some other thoughts on that. BOLLYKY: So just a little bit, and then—I'll start. I think there has been some effort for them—in terms of the cuts—at the federal level to U.S. public health employees because it was done largely around probationary employees—so less in a targeted manner and more where there might be the legal flexibility to pursue those reductions in force—you've lost a lot of people with particular expertise. So this was famously, has been reported, you saw that at USDA that the office that they had assembled around tracking the avian influenza outbreak had been gutted. You saw that at parts of the FDA, where, you know, we had brought in—or, the FDA had brought in, rather, people with particular areas of expertise that they've had to now try to hire back. EIS is an area that had been on the chopping block and, at least as of yet, given the outcry about the important role that that program plays, that has not happened. So I do think, in terms of communication, particularly from the state and local level, the importance of programs to the good work that you all do can have an effect when people have a greater appreciation of the value. I do want to point out one thing, though, that I am concerned, particularly as this has largely fallen on probationary government employees, that we are really eviscerating our next generation of public health experts and scientists. And that will have an effect not only, of course, on these people’s careers, but also on people who are considering entering the field. And it comes at a time where state and local—the state and local public health workforce has already been under stress due to the pandemic and is at low numbers. So really, the combination of this disincentive, losing potentially a generation of people, with some of the fatigue that is going on at the state and local level is really quite damaging. So again, you’ve—if you value these programs and particular areas of exchange with the federal government that are important to you, then don’t be quiet about it. JUTHANI: If I can just add one other piece to that, which is in my former role in academia the cut to indirect rates in terms of NIH funding, which funds many different types of support of research in academia, it has also had a chilling effect in the academic world where some academic institutions are not taking on graduate students in a variety of different areas. And in terms of the pipeline you talked about, of people doing research and not being able to pursue that research, some of that is because academia is feeling the pullback, whether it be from NIH dollars, a little bit different than some of the other public health funding that we’ve been talking about, more about scientific research. But really, this is an ecosystem and a continuum where people train in academia and then enter the private sector, enter the public sector, and really continue great scientific work. And it has been the stance of the United States for many, many decades that we wanted to invest in science, and scientific development, and that scientific pipeline. And so I do have concerns and worry that not only are we taking a hit to the public health workforce and generation of public health workers, but also to the scientific workforce writ large. BOLLYKY: Irina, I'm just going to add one quick thing, if I may, on that point. I have a particular concern about infectious disease research. One change, that there's proposed legislation in Congress but also apparently some support of the incoming team at the NIH, is to split NIAID, the portion of NIH that focuses on infectious diseases, into three subgroups—infectious disease, immunology, and autoimmune diseases. The thought is that this might build on some comments made during the campaign to defund or decrease funding to infectious disease research. And it really couldn't come at a worse time, given the range of things we're following. But it is not a lucrative area of medicine, to begin with, and to limit the research opportunities for people in this field is going to be a real disincentive to people pursuing it. FASKIANOS: Thank you. JUTHANI: As a—I’m sorry if I could just say one other thing. FASKIANOS: No, go ahead. JUTHANI: As an infectious disease doctor, I can attest to the fact that it is not one of the most lucrative areas of medicine. But I can also say that when we talk about public health we often think about communicable diseases, and infectious diseases being a large part of that, and the noncommunicable diseases. And we—because we've been able to have great scientific advances on the communicable diseases—in our vaccine programs, and antibiotics, and treatments, and antivirals—we've been able to focus on the noncommunicable diseases, meaning heart disease and cancer, and the things that take many, many decades to get worse in order to then cause worse morbidity and mortality. But if we don't have control of the communicable diseases that generally have morbidity and mortality more immediately, we will be losing decades of progress that we've made in public health. FASKIANOS: Thank you. I’m going to go next to Bill Taupier, who’s the director of administration and safety, in Massachusetts. Q: Oh. Thank you for having me. My question has to do with a little bit about USAID, and where it has been essentially eliminated, for all intents and purposes. My question is about, you know, outbreaks overseas, and how we can—you know, we learn a lot from those to fight diseases at home. But what is your opinion going to happen now with outbreaks of things like Ebola or Hantavirus, or other places—other diseases that could go unchecked? BOLLYKY: We’re going to be at greater risk. I think there might be a perception among some in the U.S. public that because of the struggles we saw around the COVID response, not just in the U.S. but other countries as well, that we really don’t know or are unable to contain—prevent, detect, or respond to outbreaks of dangerous diseases. And it’s not so. If you just take viral hemorrhagic fevers, things like Ebola or Marburg, you think about the Ebola outbreak in West Africa in 2013 to 2015, a little bit in ’16, that took 20,000 lives, or more. It costs billions of dollars in terms of the response. With each subsequent outbreak of Ebola virus, as well as other hemorrhagic fevers, we have gotten much better, even in low-resource countries, in containing this. The reason why you do not hear about these outbreaks in the same way that we heard about that particular West Africa Ebola outbreak is because of the build-up of these systems. USAID funding is responsible for the identification of the first COVID case outside of China. It is responsible for the development of the vaccine that we now have against mpox, and the world uses. I mean, the list just goes on and on and on of how these have kept us safe. And I do have concerns in these environments that—with the cutting of these programs, that we may not see that persist. If you had asked me even at the start of yesterday I would have told you that I think that some of the treatment programs around HIV or malaria, around in terms of the use of insecticide-treated bed nets, that those programs will probably survive in some form, even at the State Department. But we did learn overnight, with the cutting of these programs that I mentioned, or these grants, that many of the programs that had received waivers, the grants supporting those programs have been cut anyway. So I don't—I really can't say what's going to happen, but your question raises a real concern that gets at the heart of safety for all Americans and people worldwide. FASKIANOS: A question from Laura Bellis, Tulsa City Council member. Q: Hello. Yeah, I'm a Tulsa City Council member here in Oklahoma. And I also work in maternal-child health. And obviously, just geographically proximity-wise, too close to Texas for comfort. And our vaccine rates are also, as anyone can imagine, low, relative to where they should be. And so I'm curious if you all have any advisement, when we look at—whether it partnership, as Manisha has mentioned, with, you know, our state or local health departments, just what we can proactively do, acknowledging that we are likely to see a measles outbreak here? That we are in a certain type of policy and health environment that is not always very pro-public health. And just curious if there's anything you all would recommend trying to proactively do in the time we have prior to an outbreak. JUTHANI: Yeah. What I would recommend is, first, getting some knowledge with your local health department and state health department on areas that may be under-vaccinated right now. They should have eyes on that. They should know where those pockets exist. And, you know, like you said, proactively doing some of those interventions. And we do get funding to do this type of work, where we go within communities, identify what some of the barriers to vaccination may be, try to do that type of ground-building and communication with communities in terms of helping to overcome whatever vaccine hesitancy may exist, and then have vaccination campaigns to be able to, in fact, allow increases in vaccination rates. That’s some proactive work that could be done right now. Of course, you know, many health departments are stretched thin as is. Of course, we are dependent on our funding to be able to do that kind of work. But right now, I would say that that type of work is possible, and I would encourage you to connect with your local and state health departments. You know, every state is a little bit different. Connecticut is a home-rule state. We have fifty-nine local health departments and/or districts. I know that there are states like Massachusetts that have many more. There are others that have county-level government, and so there is a lot more economies of scale. But that's where I would really lean in and start there, to try to prepare yourself for what you've identified as a potential risk. FASKIANOS: Tom, do you have anything? BOLLYKY: Yeah. The only thing I would say here is part of what’s been hard about this first month is that, you know, vaccination rates have gone down. I think there is an important national conversation to be had. The part of the secretary of HHS confirmation hearings that resonate with me is being transparent that vaccines have a balance—all medical products have a balance of benefits and risks, and talking in those terms. I think it’s important that we engage in populations in a respectful way. I thought the advice that was just provided is very useful in that regard. I think there is work to be done. I think the fact that we did see a death, tragically, yesterday, hopefully provides an example of what the cost of under-vaccination might be. And there may be more receptivity to these vaccination campaigns than we might otherwise find. So I think looking for a way to have respectful, transparent conversations at this moment, given the national attention to this issue, is important. So I thank you for worrying about it. And, you know, the support you might be able to—or, the partnership you might have with your state and local officials. FASKIANOS: Great. I’m going to go next to Destini Cooper. If you could identify yourself, please. Q: Can you hear me? FASKIANOS: Yes. Q: Hi. This is Destini Cooper. I’m a policy analyst at the Legislative Council here in Nevada. And we're actually in our legislative session right now. I have a public health background. And I kind of want to know what you think the kind of pushback on public health will be when we're already in the world of vaccine hesitancy and things of that nature? And I just feel like in a world where we're trying to restore health—trust in the health care system or in the public health world, do you think that this will have some type of backlash? Because, as we know, as funding goes down or funding is taken away, then we lose services and we lose—you know, vaccine accessibility goes away, and people get sicker because we have more uninsured. And then the blame is, oh, well, vaccines don't work. Now we have more sick people. And now things that we made great strides in are now going backwards. So do you think that public health will kind of get the blame again when, how do I say it, basically options are taken away? Like, when we have to pull back on services and stuff, do you think the increase in health outcomes and, well, the lack of health outcomes—I guess, the decrease in health outcomes, do you think that public health will get the brunt of that again? Because COVID was our fault, right? Nobody believed in public health until COVID came, and then it was, oh, public health is here, and it’s terrible. So do you think that it’ll kind of be our fault again when we lose funding and we have to roll back these programs and the world gets sicker again, for lack of a better term? FASKIANOS: Who wants to start? (Laughs.) JUTHANI: I guess I can start. You know, I—Destini, I appreciate that comment. I don’t know that I would have thought of it that way, but I guess anything is possible. I would not have predicted the way the COVID pandemic happened and the divide that we ended up in after seeing a remarkable development of a vaccine that has saved millions of lives. So, you know, I think, to your point, is there a narrative or dynamic that has been set up that that could happen? I guess it could. You know, I guess I would have liked to think that with a reduction—and more health care problems, with a reduction in public health and preventative measures, that people would see that difference. But, you know, I guess we don’t know. My perspective in general is to try to work within my circle of influence, figure out where I can actually try to make a difference, and make a difference there, in that circle of influence. Because otherwise these questions become existential and feel like we’re never going to be able to make progress. But if I can look at—for the state of Connecticut, can I try to show people that I genuinely care, that I have read the science, and that, in my medical opinion, this is their best path forward, and try to bring people along and meet them where they’re at, then I’ve done my job for the day. And I think that that’s all we can each try to do. I hope we don’t end up in a place like you’ve outlined. Is it possible? I guess it could be. BOLLYKY: Two things, just to say quickly. We do a lot of work—have done a lot of research here on the drivers of differences between countries, how they did during the pandemic, controlling for relevant biological factors, and at the state level. And what a lot of that research has shown—and I’m happy through Irina to circulate the Lancet studies we’ve done on these things—is that, you know, trust—social trust, how communities interact with one another, played an outsized role in the differences between outcomes. There is actually a fair amount of research on how to engage with people who may not be trusting of public health or more inclined to blame public health for the problems. It is leveraging local—the people that are more trusted in those communities, physicians and nurses, the people that you engage with every day, the institutions you engage with every day, maintaining those relationships even in between crises, I think, is honestly one of the major lessons of the COVID pandemic for me, at least. And I think one that is going to be important in this moment. The second point I would make is I read an op-ed by a former Democratic political operative in the New York Times that talked about one strategy around this moment, from that political perspective, is waiting for the consequences of some of these actions to manifest, and therefore pointing out the folly of them. And I will say, from a public health standpoint, I don’t want that. I don’t want to wait that long. (Laughs.) I think we really need to be clear about what the consequences might be and try to engage with communities in an open and transparent way up front. And, you know, I think it’s really incumbent on all of us to do as much of that as possible. FASKIANOS: Thank you. There’s a raised hand, a number begins with 856, no name. So you’ll have to really help us identify yourself, your name and affiliation, please. Q: Yes. This is Laurie Lehmann. I’m City Council, Cape Coral, Florida. And I just want a clarification. You know, obviously, no one has mentioned Florida. Would my best bet be to talk to the county-level or the state-level public health departments to find out where we are lacking and what we can do about things? JUTHANI: Your local health department is always the group that is the most close and proximate to the conditions of what's going on, on the ground in your situation. So I think that that would most certainly be what I advise anybody, honestly, in any state, because they really know what's going on, on the ground most close to you. They can reach out to experts, whether it be at the state level or at the CDC level, to get additional information should it be necessary. So I think your instincts are correct to lean on the people who are closest to the ground where you are. FASKIANOS: Great. There are no more raised hands, but just a question about sources of good data. At the state level are there other organizations who are compiling the data that you could commend to people? JUTHANI: I would say that I think that this is a fluid and evolving situation. I think, to Tom’s point, we know that a number of CDC websites came down, and then now are back up. There are other things that are coming down and are—look to be permanently down in other agencies, as he mentioned the most recent changes that we’ve heard from USAID. So I think we’re going to need to keep on evolving and reassessing as time goes on. You know, I think there is the opportunity that maybe there will be other organizations, whether it be foundations, whether it be independent organizations, whether it be philanthropy, whether it be academia, whether it be partnerships of the like, who may try to fill voids that may develop, but I think we really don’t know what those voids are just yet. And trying to figure that out is, I think, where we are right now. FASKIANOS: Great. And, Tom, how would you say that other countries are beginning to fill the void of the leadership role of the United States in the global public health space? You know, with the exit from WHO, I mean, what is on the horizon here? BOLLYKY: Great question. I think, unfortunately, the events of the last month have had several knock-on effects. One is that governments who might be more politically aligned with the White House at the moment, some of them have—Argentina withdrew also from the World Health Organization, to emulate the action taken by the U.S. Reportedly, Hungary and Russia are considering doing the same. So this may spur, among some governments, emulation. In terms of the broader conversation about the Ukraine conflict, and indicating a potential need for more of a European role on defense on the European continent. This week, the U.K.—which outside of the U.S. is the largest government donor to global health—announced that it would decrease its foreign aid budget from 0.5 percent of GDP to 0.3 by 2027, so that it could invest more in the military, in response. Germany just, of course, had an election. There's enormous economic pressures going on in Germany right now. Germany has historically been a supporter of multilateralism, in the World Health Organization in particular. The World Health Organization has an office in Germany that does surveillance, data surveillance. I think there is some risk that you will see a pullback there as well. In terms of in-country, I think there have been some moves by aid-recipient countries to assume more of the burden. You've seen that in South Africa and Ghana, some conversations for that. But right now, the average government in sub-Saharan Africa spends $92 per person on health, which is less than a fifth of what it is in the less—the next lowest region. And their ability to assume some of these programs is going to be limited, outside of a handful of countries that are better resourced. Where we do see some governments responding has been China, particularly in countries where the U.S. has—or—and China has been grappling for influence, Southeast Asia and some Latin American countries. You've seen China offer to pay for some of the programs. I think in those strategic countries you will see that. I think overall China is not likely to assume the burden for U.S. programs in less strategic regions, or focusing on cross-border health threats. They tend to focus more on infrastructure projects. So we will see less of the focus on global health security and infectious disease or mother-child programs and more focus on healthcare infrastructure and products. FASKIANOS: Great. Roberta Smith from Routt County Public Health asked about programs like the polio eradication programs and Peace Corps, assuming they are also in danger. And then there's another question from MaryAnn O'Connor, who's the Massachusetts director in the city of Medford. Who's on the ground working on the outbreak in the Congo? So maybe you can just put those together. BOLLYKY: Yeah. So just quickly, on polio eradication, the U.S. provided money to the World Health Organization in two forms. One, like all governments, it pays assessed contributions, effectively membership dues. And then the other way is voluntary contributions. We, the U.S., historically provided significantly more in voluntary contributions. Much of that money went to two areas—the emergency program of the World Health Organization and polio eradication. So the withdrawal from the U.S. from WHO is going to have a consequence. Another major funder of polio eradication has been the U.K. government. So I don't know what will happen there in this area. It has been a priority for the Gates Foundation, so you may see them step up somewhat. But you may see some consequences. I have not seen anything in terms of the Peace Corps program. And maybe that will continue, but it’s difficult to know if they just haven’t gotten to it yet or if that’s more of a decision. I just haven’t seen any discussion. FASKIANOS: Great. Manisha, I wanted to give you a minute just to wrap up, and then I wanted to go back to you, Tom, just to say a few words about Think Global Health, because I think this community, this group could really benefit from it. So, Manisha, over to you before we close. And then we’ll go to Tom. JUTHANI: I think I would just make a plug to everybody that a lot of public health is local. And we do rely on federal partnerships and, obviously, international partnerships. But all of you are on the ground in your local communities. Advocate for public health locally. Press on and support the public health people that are doing that hard work and getting a lot of, potentially, counter messages to the work that they’re trying to do. And support them. Support the young people who are trying to do this work in that space in your local communities. And don’t be silent if you value public health, because I think that is going to be helpful not only in your state legislatures but at the federal government as well, to be able to show how public health has helped in terms of our society. FASKIANOS: Tom. BOLLYKY: Great. Thank you for the kind opportunity just to put in a plug for Think Global Health. It’s our online magazine that looks at how—tries to take—much focus on health is how things affect our—other things affect our health. This website looks at how health shapes economies, societies, and everyday lives. It looks from the other way. It’s a form of investment. I think we saw that in the pandemic. I think some of the political upheavals here are also related to what happened in the COVID pandemic. It is a multi-contributor site, so we do have a fair amount of domestic coverage of what’s happening in the U.S. So I would encourage you all to read it, but also, for those that are looking to write on these areas, we have that opportunity as well, and we welcome that. FASKIANOS: Wonderful. Well, thank you both for this hour. We really appreciate your taking the time and for the work you are obviously doing. And to all of you on the call for the work that you’re doing in your communities. It does take a village. We will be sending out the video and transcript. And we can put together some of the resources that were mentioned during this call. And, as always, we encourage you to visit CFR.org, ForeignAffairs.com, and, of course, ThinkGlobalHealth.org, that Tom just mentioned, for the latest analysis on international trends and how they are affecting the United States. And we welcome your suggestions for future webinars. You can email us at [email protected]. So, again, thank you to Commissioner Juthani and Tom Bollyky for this conversation. And we look forward to continuing it down the line. So thank you all.
  • United States
    What’s Next for Global Health?
    Play
    Following recent U.S. policies to refocus development spending and engagement, including the U.S. withdrawal from the World Health Organization, panelists discuss how the global health community can adapt its policies, programs, and financing. Please note there is no virtual component to the meeting. The audio, video, and transcript of this meeting will be posted on the CFR website.
  • United States
    Virtual Roundtable: The Pandemic Agreement and IHR Amendments After the World Health Assembly
    Play
    In response to COVID-19, member states of the World Health Organization (WHO) have been negotiating to create a pandemic agreement and to amend the existing International Health Regulations (IHR). The negotiations have been closely watched as indicators of global health diplomacy's future in an increasingly divided world. On June 1, the WHO's World Health Assembly approved amendments to the IHR and extended negotiations on a pandemic agreement. Dr. Suerie Moon, codirector of the Global Health Centre at the Graduate Institute of International and Development Studies in Geneva; David Fidler, senior fellow for global health and cybersecurity at the Council on Foreign Relations (CFR); and presider Thomas J. Bollyky, Bloomberg Chair in Global Health at CFR discuss what the World Health Assembly's decisions on the IHR amendments and the pandemic agreement negotiations mean for global health security, equity, and governance.  
  • Health
    Virtual Roundtable: A Conversation on Food and Nutrition Policy With Francesco Branca
    Play
    FRIEDEN: Thank you so much for joining us. I'm delighted today that we have Dr. Francesco Branca with us for a conversation about nutritional issues very broadly. Francesco is Director of the Department of Nutrition and Food Safety at the World Health Organization in Geneva. And I can say that I've worked with Francesco for many years and found him to be always insightful, always constructive, and someone we can learn from and work with. So, I'm going to start with asking Francesco to make a set of general remarks, then I'll be discussing some of them with Francesco, then we'll open it up for conversation with all of the participants. Francesco over to you. BRANCA: Well, thank you very much, Tom. And if I can say, I've been privileged to interact with you and with the organization Resolve to Save Lives that you chair. This has helped a lot in making headway in food and nutrition. And you realize—after my brief introduction—why I feel so. So, thank you for the partnership and thank you for inviting me to this very interesting conversation. I look forward to the interaction with the audience. I actually would like to start by giving my perspective on why food and nutrition are global challenges for health and development. And I think, you know, there are at least three reasons for that.  And the first reason is the health reason. Really, all together, one third of the deaths and about half of the disability burden is accounted for by factors related to diet and nutrition. Unhealthy diets is accounting for eight million deaths every year, obesity: five million deaths, maternal and child malnutrition: three million deaths, and unsafe food for a hundred-thousand deaths every year. But this is probably an underestimate because food systems affect health through other pathways to production practices, for example, to the use of antimicrobials in in animal production, to the use of fertilizers and pesticides that have an impact on Earth through the environment to the health of food workers. So, it's really a much more comprehensive assessment that we should make on the of the impact of food system nutrition, and health.  Then the second is the impact on the environment: twenty-five percent of greenhouse gas emissions, two thirds of freshwater use, over one third of Earth's landmass, the impact on biodiversity—as I said, the use of nitrogen and phosphorus fertilizers. So, it's a multiple set of impacts. And any economic impact of food system—and I just would like to say, and I'll put the link in the chat that just on Monday, yesterday, the report of the Food System Economic Commission has been released. And that report really gives an incredible description of the impacts, economic impact of food systems. And you know, the conclusion of the report is that the costs of the current food system are far larger than their contribution to the global prosperity. You know, the unaccounted cost of the burdens they place on people on the planet are currently estimated that fifteen trillion U.S. dollars a year, which is equivalent to twelve percent of GDP in 2020, which, by the way, is exactly the same figures as the expected turnover in the sector in 2030. So, you know, almost the same amount, you know, in terms of wealth and the same amount in terms of negative externalities. So only the health costs are eleven trillion US dollars.  By the way, obesity on its own is four trillion dollars, three percent of GDP, plus the three million environmental costs. And then we know that actually food systems are related to poverty. In Europe, we're now seeing the rebellion of the farmers who see their income threatened by the global crisis and you know, the price it's paid on their food which is inadequate. So, you know, the small farmers are challenged, but then also the system is such that a healthy diet is unavailable and affordable to three billion people in the world. The trends are not encouraged, because, you know, unfortunately food insecurity and undernutrition is covering. The improvement with adding nutrition targets, particularly stunting, is been relatively good. But the balance between the decrease in undernutrition and any increase in obesity is not leaving us in a better situation in the future.  What's been the policy response here? I was, together with colleagues in FAO, organizing the second international conference on nutrition back in 2012. And in that conference, we basically had the support of the global community on a series of targets, global nutrition targets, and noncommunicable disease targets that basically frame the narrative on food and nutrition in a much more comprehensive way. So it's not about as it used to be only about food insecurity. It's about a healthy diet. And it's about the prevention of noncommunicable diseases.  And in that conference, there was a final document that was calling for a comprehensive multisectoral response on health systems, food system, trade, social protection. Sixty-two specific recommendations all evidence based, so there was a very clear picture as this as this has been implemented. Frankly, the answer is not really, not really. Even recently, when big initiative which has been launched by the Secretary General of the United Nation, UN Food System Summit, last year, we just had a two year follow up the stocktaking. It was a large mobilization, but very limited policy commitments all entirely voluntary, the UN Secretary General call to action of this last stocktaking is very much open ended. It says you need to think about the food system. It's important for sustainable development, you need to engage all sectors and stakeholders, you need to invest in innovation and technology. You need to engage with business. But yeah, very general call to action.  COP28 was quite interesting. It's—the concept of sustainable healthy diets has been mentioned in the health declaration and the food declaration spoke about the impact of climate change on food production, but it really did not commit to any food system transformation. Now, the Food System Economic Commission estimates that two hundred to five hundred billion U.S. dollars a year are needed to transform, radically, the food system, but the benefits would be five trillion U.S. dollars a year. Going specifically on the specific issues: obesity.  Obesity, I mean, basically, the trend has been going up. You know, very few countries have been able to make a change. We've seen some change in some European countries in some sub areas, maybe regional changes, even actually, the United States has been some communities that have shown some change, but largely the change has not been there. The policy response has been inadequate. And the World Health Assembly asked WHO to do something about it. We developed what we called an acceleration plan, basically saying yes, obesity is complex. But can you do at least five things which we know are cost effective? Can you establish taxation of sugar sweetened beverages can you have warning labels to inform consumers that they should, you know, prefer certain products to others? Can you stop marketing for—to children? Can you have healthy public food procurements, physical activity in schools, and integrated health services in primary healthcare that understand the issue of obesity? So, these are fairly basic things. And thirty-one front-runner countries have responded to that. But you know, fifteen countries have committed to establish as a sugar taxation but you know, in a sense it’s a drop in an ocean yet.  Early nutrition, early nutrition. We know that early nutrition is good for the prevention of undernutrition and the prevention of obesity. And we've done well in improving breastfeeding rates, ten percentage points in the last ten years. But you know, code-of-marketing breast milk substitutes, only thirty-seven countries are implementing it entirely. Maternity protection law is not implemented. Baby-friendly hospitals, you know, how many hospitals are really done in a way that, really, breastfeeding is supported by adequate—adequately training health care workers.  For the environment, you know, the kind of policies that would make the food environment more conducive to healthy diet support is still, you know, a lower number of countries and also the well-known ways to deliver those problems are not implemented. For example, sugar taxation, no taxation of sugar sweetened beverages, yes, many countries do it, I think we have about eighty countries doing it. But you know, how many really have, you know, the taxation at the level which we know is going to produce an impact? Front-of-the-pack label, in Latin America, we have this warning symbols, which have shown to be effective in shaping consumer choices, but you know, others, other countries and other regions in the world, Europe, Australia, U.S.—scoring systems, which do not have the same impact.  And then finally, finally, you know, what we've been really working with, with Tom and his colleagues—the reformulation of process food—that's an area, but actually some remarkable impact has been demonstrated. Trans-fat, we now have forty-six percent of the world population is covered by policies that, you know, eliminate this compound, you know, which is industrially produced, industrial trans-fat, you know, for all the population. In the Americas—it’s actually this is even better. America is about to be declared trans-fat-free: eighty-five percent of the population seems to be covered. And you know, this change going in, you know, in only a few years—from six percent to forty-six percent coverage—has saved a hundred and eighty-five thousand lives. So, it's remarkable what you can do.  But also, you know, for example, very limited success. There are clear benchmarks, we know what, how much sodium should be in processed food, many countries, actually, in many countries, the intake of sodium mainly comes from processed foods. So, changing the content of salt in processed food would produce enormous benefits. Industry has not been willing to commit to changes. And again, the regulations there, the regulatory environment is not really making the change.  So just to conclude, basically, the challenges are enormous. The reasons to make the change are there, the solutions are there, but the policy commitment is not there. Can you speculate? Is it because of commercial interest? It’s because of you know, you know, capacity issue, and you know, capacity to develop? It's a complex system and food systems are complex. It's a capacity to really develop the right measures? Now we can discuss it, but the fact of the matter is that the action taken has not been sufficient. That's why we are in this situation. Thank you. Back to you, Tom. FRIEDEN: Thank you so much, Francesco. That was a whirlwind tour through the world of, of nutrition policy and where we are as a country, as a world, as a community. What I'm going to do is, I'm going to ask a few questions, and then in about fifteen minutes, we'll open it up for questions from any participant. Let's start with the good news. There are areas of progress that—you mentioned trans-fat for one—you mentioned, the Latin America front-of-pack warnings for another, in other contexts. And you mentioned also baby-friendly hospitals and a steady increase in breastfeeding. So, what can we learn from those successes? What can we learn from that progress? What are success factors that may be able to be applied to make further progress there, and also to extend that progress to some of the areas that are making less progress? BRANCA: So, I would say, first of all, you know, a good description of the issue, of the challenge with data. I think data are really important to understand, you know, what is what is the burden—health burden. We need to understand what is happening in the food system. So, for example, what is the content of these different compounds in food, so you know, good knowledge of the space.  Second is science. Contribution of science that has designed programs in a way that we could demonstrate effectiveness. I think that's important to convince that a certain measure, you know, may have a cost and we're able to assess the ratio of cost effectiveness. And that is important to persuade policymakers.  Third, a clarity about how to implement these things. So, you know, the trans-fat elimination, we need to understand exactly the different elements in the process, we need to see where the measures are needed. And we need to see—understand who the stakeholders are. So, for example, in the, for the trans-fat, it was really critical to have, this—what we call the replace package. So, a series of, you know, policy briefs in which we say, okay, this is how you do the monitoring, this is how you engage with the stakeholders, this is how you communicate. So, clarity about the measures.  And then really, probably one of the most important is generating the consensus. Generating the consensus, which requires civil society, media engagement, even for difficult agendas. Just to give an example, meet some of the warning, but you know, even before that, the taxation of sugar sweetened beverages in Mexico. That could only be done because of the deep involvement of civil society, you know, the organization called El Poder del Consumidor, or the Institute of Public Health in Mexico. And these people risked their lives, I mean, they were personally challenged. So, you need a very energetic civil society, of course, supported by UN organization. So, you know, creating basically a social movement around those measures. I think these are the success stories. For breastfeeding, definitely the—this is also the case, but you know, having a broad movement, including the people who are involved, including, you know, the mothers, including the health workers, so that has created the consensus that led to the adoption of defective—of defective laws. FRIEDEN: Great, very helpful. So, what I heard was technical, proven policies, pocketbook argument, money, clarity on how to implement, a social movement with partnership between civil society and government. And you also mentioned the importance of individuals willing to step up. I think in Chile, which had the first front-of-pack warning, it was perhaps one legislator who pushed for it year after year. Can you say anything more about how that kind of partnership between government and civil society can be most effective—where it's worked well and where there have been problems? You've mentioned in the past the breastfeeding movement, where there's possibility with synergy that wouldn't be there otherwise. BRANCA: I mean, I think in Chile is a good example. And personal leadership is important to me, definitely I mean in Chile, the fact that we had basically a member of parliament, the head of the Health Commission, who worked you know, in a sense in a bipartisan way that was that was really important. I mean, other good examples in the breastfeeding space has been when you know, ministers, female ministers themselves had gone through the understanding of the issue and you know, that was helping in the political commitment. It didn't work well when they were interferences—largely I would say. And then when these interferences were not overcome by adequate responses.  We still have countries who are reluctant to take on some of these measures because they have been threatened by some commercial entities who have said okay, we will withdraw our foreign investment—foreign direct investment in countries and trade agreements have been often the cause for the rapid evolution of the food system towards unhealthy food environments. And even if policies could be effective, there are interferences that try to undermine them and try to challenge the evidence base and okay, you know, if you establish a taxation of sugar sweetened beverages, there will be a reduction in the workforce. Or you know, there will be—if you put front-of-the-pack labels it will actually affect your trade and you might be challenged by the World Trade Organization.  Specific countries trying to establish restrictions on to the import of certain products, high in fat, challenge the index again, you know, on the trade basis. Even the current guidance that WHO has produced on digital marketing breastmilk substitute is challenged on the ground that, you know this violates certain trade laws in certain countries. So, I would say that, you know, the competing vested interests, that is the main cause.  But we can respond to that. I mean, we have developed a series of policy briefs, for example, on sugar taxation saying, okay, are these arguments, you know, solid? In reality, you know, there's no evidence that the establishment of taxation of sugar sweetened beverages has had any effect on employment rates. Trade laws, are they really broken? No. And you know, there are ways for of course, countries to establish import restriction, if these restrictions are also imposed on their own products, and they do not, you know, create—basically violate the competition rules of the World Trade Organization, so that it can be done so. So, there are misconceptions that are—that can be—that can be explained and deconstructed. FRIEDEN: Well, you've anticipated and answered my next question, which is, what are the main barriers to progress? And what can we do about them? How about—you talked about the science being clear as one of the success factors when it comes to obesity or sodium or some of the other nutritional factors, is there too much scientific doubt? Has that been something that has made it more difficult to act or is that just something that commercial interests exploit to delay progress? BRANCA: So, I mean, I admit that we've been able to consolidate the science relatively recently. So, when I started my job about fifteen years ago, we had some suggestions that you could go in certain directions, but then what happened? Some countries, because you know, you need, of course, it's important to have some pilot studies. We learned a lot from taxation of sugar sweetened beverages, because in U.S. cities, there were some experiments like that. Even in colleges—only in colleges, we could use that. But then what happened is that some countries basically had the courage to establish national policies. At that point, we had, you know, the information to be able to bring together the science. So, the science has been consolidating recently. So, you know, only last year, we've been able to update the, what we call the best buys for non-communicable diseases. And now we have a package of food measures for food and nutrition, which we didn't have before. And we can now prove they are cost effective. So, the science has been evolving, you know.  Also, our capacity to monitor policies has evolved. You know, in WHO we keep a database called the Global Database on the Implementation of Nutrition Action, which is, you know, several thousand document there. So, we have a good understanding of what is the policy space. So, all that understanding is contributing to make the case. So, the science is still challenged, of course, still challenged because we are not able to have the same level of certainty in analyzing policies, then when we do a randomized control trial. I mean, WHO has decided to develop guidance on policies. And so, we have last year we released guidance on marketing food to children, giving clear recommendation about regulating. You know, in the past, when member states had to agree on WHO whose policies, they were saying, well, you know, we recommend to do something, but it can be voluntary. Now, with our scientific analysis, you say, no, sorry, voluntary, we have the evidence, it's not effective. You're not going to be able to achieve that. So, you need to have regulation. So, that’s with the marketing policies.  We're about to release also a guidance, guideline on taxation of sugar sweetened beverages, another one on labeling, another one on public procurement of food. But in some cases, you know, the way we analyze the science as well actually the evidence is moderate quality, because you know, the nature of the evidence because you know, when you analyze, you know, these policy cases, you know, you cannot have a control, for example. And the kind of data we have, you know, could be somehow considered to be partially biased. But elsewhere, I think we're getting better, and also evaluating the policies. And whenever, you know, countries set up policies, we ask them to make a good, you know, to set up a good evaluation system, because that will benefit everybody else. FRIEDEN: One of the hot topics is ultra-processed food. You have in Latin America, a big focus on trying to reduce consumption of ultra processed food, you have some debate about what the definition is. What's your take on this topic? BRANCA: So, I must say that we have been discussing this, and at the moment, WHO doesn't use the term ultra-processed food. We prefer to say highly-processed, because, you know, we consider this as an important element, but we don't want to be at the moment seen as fully sponsoring the concept of ultra-processed food which is based on a specific classification, which is the NOVA classification. It's a very interesting concept and we believe it's important because it doesn't only bring together the—and actually make it much more scientific than what we used to call junk food now, makes it much more objective—doesn't only refer to the nutrition composition of these foods. You know, high-fat and sugar, so that is what they used to say in the past. Yes, that's, that's some characteristics of these foods. But there's another component and that’s the component of the, of the disruption of the of the original food matrix. You know, having an impact on absorption of nutrients, and creating something which, you know, has been demonstrated by many studies, very important, which is addiction.  Addiction, so addictive behaviors, would, in a sense, make this kind of food similar to what has happened with tobacco. So, in a sense that, then that leads out the argument, it's actually these foods have been chosen freely by individuals. No. They have been pushed on people who then have become addicted to them, and then, you know, it’s beyond their control. So that requires some form of control limitation. So that's an interesting, you know—plus the other component of the food which make them appealing, you know, which also contributing to their addictive power, you know, the use of certain additives, the use of certain—that, you know, for example, make them more appealing from the appearance point of view, the packaging may be improving the convenience. But, you know, how do we define all these elements in a more rigorous way? And above all, you know, how can we act on them.  So, the definition is absolutely critical to be able to define response measures. So, it is our intention to do more work on this, and to build on the excellent work which is now being done by many scientists all over the world. Now, starting from Latin America, but really covering, you know, many parts of the world. You know, I've just seen a report that we have done in the Asian region, you know, describing how they had the highly processed food, really have, you know, taken up and they are rapidly spreading in that part of the work, which already has an incredible problem of non-communicable diseases. FRIEDEN: If I'm understanding you correctly, what you're saying is: perhaps we should be thinking not so much about ultra-processed or highly-processed, but highly addictive food, which may then require a different approach. BRANCA: Possibly, but, you know, we need again—there are ways to do that, and there's this very good science about how to measure effectiveness, but, you know, I think the challenge there is the—is the definition and currently in the definition of ultra-processed foods, there are gray areas. You know, the interpretation in different parts of the world may be different. So, if we are able to do that, yes, I think you know, if we're able to come with a series of, you know, characteristics of the foods which have finally, a negative health impacts and define them then we can define a response strategy much more, much more effective. FRIEDEN: Great. Now, we can just turn to the CFR colleagues to outline how people can ask questions. OPERATOR: Absolutely. [Gives queuing instructions.] Thank you, Tom. FRIEDEN: Thank you very much. Let's delve a little bit more deeply into the issue of addictiveness. Is this the new frontier for how we should think about what should be regulated? Is it all about sugar sweetened fat? Is it all about increasing tolerance and increasing consumption? Is this an area where there's possible policy progress? BRANCA: I mean, definitely, sugar is a nutrient we should try to tackle much more effectively. The exposure to sugar unnecessarily starts from early in life, starts from you know, foods that are designed for children. And then it stays on and then we have ample opportunities to consume much more than what WHO recommends, which is maximum ten percent of energy from sugars, which, you know, if you translate it in a drink is probably less than one can of soda per day, you know. And then you don't eat anything, any sugar, any anything else than that. So, sugar is definitely important. And sugar, the way it's actually consumed through highly processed food can be responsible for an effect—a neurological neurobiological effects, there are demonstrated mechanism that then can lead to that reward mechanisms, for people look for that, and that's actually the starts of the addiction phase. So probably, that would be one of the nutrients to focus on. We say that, you know, we need to have healthy diets and we need to consume whole grains, for example. So similar to sugar could be refined carbohydrates, which could have a similar mechanism of action. So that's where I would say that we have to start.  The other important nutrient of course is sodium. Sodium is actually the number one killer. If you look at that number, I gave you eight million deaths every year from unhealthy diet, and then you say, okay, which other components of unhealthy diet you're looking at, then you have sodium—excess sodium, which is number one—then you have a number of insufficient intakes. So, you have insufficient intakes of whole grains, fruit, vegetable, legumes, and then you have high intake of fat, trans fat, red meat. So, sodium is the one we have—and of course, you know, sugars. So, sodium is the one nutrient we have to address together with sugar if we really want to, you know, make a big change in people's health. FRIEDEN: Great, now we've got some questions from the group. Let me start with Valentina Barbacci. You can—you can speak. Q: Yes, wonderful. Thank you. Can you hear me now? Wonderful. Valentina Barbacci, based in London here, Term Member at CFR but also based with CEN-ESG. I'd be grateful for your thoughts with regards to the impact of endocrine disruptors and hormone blockers that are increasingly showing up in various you know, not just food, it's also baby products, you know, hygiene products, all sorts of things that are from—range from adult to infant care products. So, it's also in foods but predominantly in health care products as well—sorry: self-care products. And what can be done to bring on sort of voluntary disclosure directives that might then eventually lead to mandated disclosures, much like we've seen with TCFD and TNFD mandating climate and biodiversity disclosures that were initially voluntary, but have now become—or are becoming—mandated so that this kind of tip the—tip the curve a bit and perhaps that we could see something in the health side with regard to that? Maybe I'm naive and optimistic, though I welcome your thoughts. BRANCA: No, I think you're right. It's a very important topic. When we’ve been looking at obesity, we've been trying to be thorough, and really look at many different outcomes, including endocrine disrupters. It is a possible mechanism. Of course, it's an important mechanism also for other for other aspects. But for obesity, we didn't really find a major role in endocrine disruptors. Definitely the endocrine disruptors have a much greater role for other aspects of health, including reproductive health.  So, from the food point of view, you're quite right, you know, we would need to look at it more carefully. I think in Europe, there's been much more experience—there have been some interesting reports. So, I think it's been looked at more carefully. I think we are, we're not ready with that. I think we need to do much more work to be able to describe the issue. And then maybe come up with some recommendations. But it's on—you can imagine, you know, the list of things we need to look at, it's very broad food system is very broad. Endocrine disrupters is definitely one of them. It's a large category of products. It includes some products, which are already regulated, you know, such as some pesticide plus other products which are not regulated. So, you know, thank you for reminding me that but you know, I think we are only partially able to respond to them. FRIEDEN: Next is Joel Cohen. Q: Thank you for this excellent presentation, Mr. Branca. My name is Joel Cohen. I'm a professor at the Rockefeller University and Columbia University in New York City. I'd like to ask your views on dealing with childhood stunting. Approximately a hundred and fifty million children under the age of five are stunted due to chronic undernutrition and infection. That's twenty-two percent of all the world's children. At the same time, according to FAO, the world produced 2.8 billion metric tons of cereal grains last year. At four to five people per metric ton, that is sufficient to feed adequately the calories required by eleven to fourteen billion people. We have a population of eight billion people. And yet twenty-two percent of all the children are chronically undernourished. And the reason is that only forty-three percent of the cereal grains go into the mouths of people and the other fifty-seven percent go into animals and machines. I am worried about the future of our species. And by the wastage of one fifth to one quarter of our potential problem solvers by starving their brains in childhood. Could you help me understand what would be the most effective steps to dealing with this problem? Thank you. BRANCA: Well, thank you, Professor Cohen, this is a wonderful question. And you got all the numbers, right. And those are very compelling numbers indeed. So, when WHO suggested global nutrition targets to the World Health Assembly, we had stunting, you know, in as the first one. And, you know, 2012, the target was to reduce by thirty percent the number of stunted children by the year 2025. And since then, there has been actually a good reduction. But some countries, particularly the countries in Africa or in Latin America, have been successful in making progress towards these targets. South Asia, unfortunately, has been not able to respond, at the moment actually, the largest number of children with other stunting and wasting is in South Asia. So that's where the biggest part of the problem is.  Stunting is not only a food issue, stunting is a combination of issues—is about access to health and health care. It’s about clean water, it’s about adequate care by caregivers. So, there's been a reduction of stunting, because of the improvement in food security, or health care in some parts of the world, but not in other parts of the world. We're not going to achieve the 2025 targets, unfortunately. COVID made things worse. So, you know, if we have a curve of reduction, that curve actually flattened, and we had many more children who didn't stop their progression to stunting. Because, you know, food insecurity hit, families were economically hit, the services were stopped, immunization decreased. So, all of that affected stunting.  In terms of food, I think what is important to remember is that I think you've made a, you know, incredible calculation of the energy side, it's actually not just the energy side, it has to be nutritious food. It has to be access to plant food, but also some animal source foods, which, you know, a small amount of animal source foods are critical—doesn't have to be meat, it can be eggs, it can be dairy, in some parts of the world, it can be insects—that needs to be part of the diet of stunted children.  We have, unfortunately, big problem of the variety of food that children eat. We have an indicator called the Minimum Dietary Diversity, and you know, you can really see there's a correlation between those stunting rates and having diets which are very little diversified, you know, almost, you know, a couple of items only per day, per child. And then you have the combination of wasting and stunting. So, there are crises that generate acute malnutrition, and then repeated acute malnutrition crises are going to increase the problem of stunting.  So, in a nutshell, you know, the response can be there, I think there's quite some investment done by countries themselves. I mean, we've seen many more countries that are home to these stunted children also scaling up a response so that—that's good news. But South Asia still has a lot to do. I mean, Indian government has set up an important program to address the stunting of children. It's about social protection. So, we need to have much stronger social protection system. Pakistan had a very good social protection system, for example. I think India is the same in some states, but it needs to scale up. So, you know, probably it's not only a food security issue, but it's a combination of actions that governments should take. FRIEDEN: Francesco, I've heard a calculation or an assertion that each episode of gastroenteritis in a developing child—in a young child sets them back a few months on their growth curve. And I think this is the point you were making, that it's not just about calories in, it's also about clean water and vaccination and health care. BRANCA: Oh, yeah, absolutely. Actually, you know, this is something that we in nutrition, learned, you know, in our 101. There was a famous study done in Guatemala, by a gentleman called Leonardo Mata. It's a beautiful book he has written and basically was looking at, you know, the weight and the height of children longitudinally. And you could see that, you know, these children had, you know, the growth curve was, you know, like, like stairs. And then, you know, the ideal curve is like this, and then, you know, they were progressively, you know, detaching, you know, you know, they have this infection here, and then, you know, they have, you know, the poor season there, and then progressive is like that. So, absolutely, I don't remember exactly the mathematics there. But you know, it's something that happens progressively also because of a degraded environment.  We're going to see more of this because of the climate change, because climate change is going to have you know, even greater problems to the quality of water to the accessibility of water, you know, plus the seasonality of food which is going to become worse. So yeah, we need to have a much greater investment if we want to really you know, bring down the number of stunted children, and I totally agree with the previous speaker that this is something which is completely unacceptable from moral—but also, you know, this is the future of our society. And we use this phrase we need to make investment to—in brain infrastructure. I mean this is this is the future of the world and of society so, societies will fail if they don't address the standing issue. Professor Cohen, thank you. FRIEDEN: Thank you, let's, let's spend a minute on the front-of-pack warning that was really piloted in Latin America, it has now spread to most of the continent or much of the continent. What's your take on how impactful that will be and how we can get other parts of the world to take that up? Europe has gone a different route, as you indicated its route that's not likely to have the same impact, can that be changed? In the U.S., I'm afraid the current Supreme Court might preclude this type of activity. It's problematic from a current legal interpretation. Corporations apparently have the same rights as people in the U.S., and it's considered compelled speech, so, it would be a violation according to the current legal regime of the First Amendment. I don't think a different reading of the of the law would have supported that, but it's probably out of the question in the U.S. in the foreseeable future. But globally, what's the potential for geographic expansion? How can we get there, and how important is it? BRANCA: So first, maybe the impact and we're looking at data. And we need to see data. I have seen some very interesting data from Chile, I believe, that are demonstrating that actually, the impact of warning on the consumption, for example, on sugar sweetened beverages was about twenty-six percent. So even more than the taxation of sugar sweetened beverages. So, you know, it seems that it has an impact on purchasing choices of people. It's quite interesting, because, you know, the wording are simple. And everybody understands them, including young children. So that's, that's, I think it's incredible power of persuasion. So, so that seems to be good. Is it going to have eventually an impact on the overall change in the diet? That's something to be seen. So we still do not have data to say, okay, this, this has, for example, reduced obesity rates. We don't, but probably because we, we need to have a combination a package of policies, but definitely warning labels may be an important measure to take. Also, because it might for example, help on some of the difficult actions, which is the sodium reduction. So, labeling has always had a good impact on sodium reduction. So, we, we should be able to say they work and we're collecting data now in the many countries in Latin America that are doing it, it's actually not just South America. Israel has done this; Canada has introduced a similar—not exactly the same but in a similar scheme. So, we need to see what happens there.  Now can this expand? Other parts of the world are using different systems so rather than saying you know, you shouldn't—you're discouraging this particular food because it has too much I too much fat, sugar, salt, we're saying okay, this is a food and you know, overall, the combination of its characteristics make—places it into a favorable or disfavor category you know. For example, France has developed called the Nutri-Score system, which is a great from A to E. A being, you know, the green one or the one which is sort of favorable, you can eat basically, you know, as much as you like. E is the is the category in red, which is discouraged. So, that somehow is an advice to moderate consumption of the categories in the E or in the higher is scoring. A similar system is the one used in in Australia, New Zealand: the five-star system.  In reality, you know, if the outcome is the decrease in consumption of an item, the warning seems to be more effective than other scoring systems. As you say, there are challenges there, definitely the warning system is fought very, very strongly from—by the corporation, and you know, because this indeed affects their choice capacity. The warning symbols are also used to connect to other policies. So, for example, you know, products with the warning symbols cannot be distributed in schools, or products where the warning symbols cannot be marketed. And so, basically, you know, this system allows a combination of policies, which are shaping people's choices. So that's, I think that's the secret of its effectiveness.  I think, you know, if we're able to demonstrate its impact, it's something that has a future. I have something quite interesting from a colleague studying the addiction of—to foods. And that is the fact that I think the argument for having legislation against tobacco in the U.S. is exactly the argument on addiction. So that goes beyond, you know, that maybe could be a way to respond to the issue of the freedom of speech, something that, you know, affects you beyond your choice should be discouraged by public policy. FRIEDEN: If only public policy were so rational in the U.S. We have time for one more question, if there's any question from the group. Meanwhile, let me ask you about the kind of best-case countries. Are there countries where you think there's a real possibility that we will substantially reduce sodium intake or turn around the obesity epidemic, because we don't have great success stories? We've seen in in various areas—Denmark, taking the lead on trans-fat, Chile on the front-of-pack warnings—but in terms of actual impact on some of these really difficult problems, we haven't seen any countries stepping up and achieving that kind of outcome. Do you see what the ingredients might be, or which countries might be most likely to succeed or to at least undertake the effort? BRANCA: I'd like to be optimistic. I mean, we have learned from countries. I mean, the whole nutritional epidemiology has been developed based on the case of Finland many years ago, who reduced dramatically the intake of saturated fat. I mean, they were dying of cardiovascular disease, you know, more than anybody, anybody else in the world. And it was changed, and it was a lot of change in the food system. It can be done. Finland was also good at reducing sodium intakes with a combination of policies, particularly the labeling, but you know, negotiation with the company's public food procurements. Now, the UK has done some interesting work, at least they brought down a couple of grams. Nobody has really achieved the WHO recommendation of five grams per day, but many countries have brought down the levels of consumption to nine grams, you know, from very high levels. So that's, I think, already good news. But there are others who are promising. I was talking to my colleagues in Washington about Colombia. Colombia has very tight benchmarks for sodium in foods, and they now have introduced a food taxation law that actually might target those foods. So, Colombia is an interesting one, for sodium. For obesity. We're really, you know, all you know, looking into what—looking forward to what Chile is going to tell us about childhood obesity. They've really done very good things, very, very effective. Portugal is an interesting country. They have also introduced taxation of sugar sweetened beverages, reduction of marketing for—to children. And you know, I've seen data—I mean, I always want to see maybe two rounds of surveys, but you know, the first round of surveys you know, there's an obesity surveillance initiative in Europe. And you know, Portuguese children seem to be less obese than they used to be before. So that's good news. So, I think we need to keep pushing, we need to keep collecting the data. We need to keep looking for advocates. And, you know, I want to be, I want to be a bit more optimistic. FRIEDEN: Great, thank you. We're almost at time. But we have a quick question again from Valentina Barbacci. Very briefly, please. Q: I’ll make it super quick, I just love this topic. Could you speak to a little bit—regarding the studies that you found in other countries—could you speak to the environment and Tom, you mentioned the U.S. environment—legal environment—but the research environment whereby studies that aren't tied to drugs or drug resolutions are not funded? But we seem to have very good examples of studies elsewhere in other countries. And so how can we raise the profile about that—you mentioned obviously support, but could there be other investment that goes into funding those studies on a larger scale to support further rounds of data? And would it be a philanthropic model? Would it be another type of model that you would recommend, something that doesn't, you know, corrupt—corrupt, the studies itself, as we often see now, and it can be tragic when that happens? BRANCA: You have a very important point. Because we have a challenge actually in finding the resources to address—in general non communicable diseases—but now these aspects of nutrition? I think we have to rely on philanthropists. I think Bloomberg Philanthropies has been absolutely instrumental to what is happening in Central and South America. Supporting civil society, supporting independent academic research; I think that that's a model we have to we have to still rely on. Potentially, there are other ways to do that. And I think Europe has some good independent research. The European Union has funded seventy-five million of a joint action bringing together thirty countries on the prevention of non-communicable diseases, it’s exactly targeting the good practice for policies. So, philanthropists, and, you know, large funding institutions, which of course, are government related. That's what we need. FRIEDEN: Great, well we're just about a time. We heard exciting things from Francesco about a clear way forward on obesity with taxation of sugar sweetened beverages, clear warning labels that will discourage consumption, stop marketing food to children—and I would say maybe not just children, but marketing, unhealthy food, generally—healthy public food procurement policies, promotion of physical activities in schools; that the best buys have been updated. There's an economic case to make, there's technical clarity. Certainly, we always need to know more, but there's much that we can do with what we know now. Francesco, I'll give you the last word, is there anything more you'd like to say or last words of wisdom on healthy eating for long, healthy, productive lives? BRANCA: Well first of all, thank you very much for this opportunity for the very stimulating questions. I’ll think more of what we can do about endocrine disruptors, but what is most important is the fact that this kind of conversation and having a community which is—we keep thinking is really important. So, looking forward to your reflections on this. From my side, I must say that we will be going further in creating also collaborations and bringing together the countries who are willing to work together. We have what we call the action networks. So, bringing—coming together to help each other or making better action and then I think that the success will encourage us to go even further. FRIEDEN: Great, thank you very much and back to CFR to close us out. Thank you so much Francesco. And thanks to the group for joining and great questions. We look forward to validating the optimism you feel that we will make real progress making our food environment healthier. Certainly, the link you sent in the comments you made at the outset made clear how much is at stake in our health, in our economy and in our environment. Thank you all so very much.
  • World Health Organization (WHO)
    Negotiating Global Health Security
    Lessons from the COVID-19 pandemic could revolutionize global health security, but the window for change is closing—quickly. In the latest Council Special Report, Yanzhong Huang and Rebecca Katz outline the urgent reforms that could lead to a safer, healthier world.
  • Climate Change
    Managing the Health Risks of Climate Change
    The health of millions stands to be harmed by climate change in the coming decades, but national governments and international organizations remain woefully underprepared. Elizabeth Willetts and Andy Haines suggest a path forward to bolter responsiveness and resilience.
  • Public Health Threats and Pandemics
    The Global Governance of Emerging Zoonotic Diseases
    Zoonotic diseases, naturally transmissible between humans and animals, have posed a growing public health threat for decades. However, existing institutional arrangements have fallen short. The wide-ranging, large-scale, and costly effects of the COVID-19 pandemic demonstrate the value of addressing those weaknesses in global governance.
  • Public Health Threats and Pandemics
    Managing the Risks of Biotechnology Innovation
    Biotechnology advances offer immense public health and consumer potential, but come with serious risks. A recent workshop held by the Council on Foreign Relations brought experts together to discuss new forms of global governance to manage those risks. 
  • Health
    Perilous Pathogens: How Climate Change Is Increasing the Threat of Diseases
    Climate change is creating many pathways for zoonotic diseases to reach people. Four cases show how the climate crisis is altering disease threats and how the world can respond.
  • COVID-19
    Preventing and Preparing for Pandemics With Zoonotic Origins
    Every viral pandemic since 1900 has been the result of spillover from animals to humans. Public health systems should take the steps outlined by Jay Varma and Neil Vora to limit the potential for spillover and the rapid spread of pathogens.
  • Afghanistan
    Women This Week: Afghan Women Rise Up in Response to Kabul Bombing
    Welcome to “Women Around the World: This Week,” a series that highlights noteworthy news related to women and U.S. foreign policy. This week’s post covers October 1 to October 7.
  • Infectious Diseases
    Why Hasn’t the World Eradicated Polio?
    The world is inching closer to eradicating polio, but armed conflicts and opposition to vaccines stand in the way of finally eliminating the disease.
  • World Health Organization (WHO)
    Virtual Roundtable: The Expanding Monkeypox Outbreak
    Play
    For the first time since the COVID-19 pandemic began, the World Health Organization is poised to declare a different disease, monkeypox, to also be a public health emergency of international concern. Since early May 2022, cases of monkeypox—a disease endemic to parts of Africa—have been identified in more than thirty-seven countries where the disease is not normally found. More than three thousand confirmed and suspected cases have been reported.  In this Council on Foreign Relations roundtable, Dr. Luciana L. Borio, senior fellow for global health at the Council on Foreign Relations, and Dr. Anne Rimoin, Gordon-Levin endowed chair in infectious diseases and public health at the UCLA Fielding School of Public Health, discuss the state of the international monkeypox outbreak, national and multilateral public health responses, prospects for control, access to countermeasures, and the potential implications of this outbreak.
  • World Health Organization (WHO)
    What Does the World Health Organization Do?
    Since its postwar founding, the UN agency has garnered both praise and criticism for its response to international public health crises, including the COVID-19 pandemic.